

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

203479Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

August 22, 2012

NDA: 203479

Drug Product Name

Proprietary: (b) (4)™ (proposed)

Non-proprietary: Clozapine oral suspension, 50 mg/mL

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
December 28, 2011	December 29, 2011	January 23, 2012	January 26, 2012
July 17, 2012	July 18, 2012	July 18, 2012	July 18, 2012
August 15, 2012	August 15, 2012	August 16, 2012	August 16, 2012

Submission History (for amendments only) - N/A

Applicant/Sponsor

Name: Douglas Pharmaceuticals America Ltd.
Address: Lincoln, Auckland, New Zealand.
Representative: John Franolic Ph.D., VP of Reg. Affairs
U.S. Regulatory Agent for Douglas 1775
West Oak Parkway, Marietta, GA 30062.
Telephone: Tel: (770) 373-5635 Alt: (914) 269-9415

Name of Reviewer: Vinayak B. Pawar, Ph.D.

Conclusion: Recommend approval.

Product Quality Microbiology Data Sheet

- A.
1. **TYPE OF SUBMISSION:** Original New Drug Application
 2. **SUBMISSION PROVIDES FOR:** A new Oral Suspension, Clozapine.
 3. **MANUFACTURING SITE:**
Pharmaceutics International Incorporated (PII)
10819 Gilroy Road, Hunt Valley, MD 21031
FDA Registration#:1000513101
 4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**
Dosage Form: Non-sterile Oral Suspension
Route of Administration: oral
Strength: 50 mg/mL
 5. **METHOD(S) OF STERILIZATION:** Non-sterile suspension.
 6. **PHARMACOLOGICAL CATEGORY:** Antipsychotic drug for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

B. **SUPPORTING/RELATED DOCUMENTS:**

C. **REMARKS:**


This new drug application NDA 203479 provides for a non-sterile Clozapine Oral Suspension, 50 mg/mL. During the filing review of this NDA, a deficiency was identified and was conveyed to the sponsor in an Information Request letter dated February 28, 2012. The sponsor was asked to provide test methods and acceptance criteria to demonstrate the absence of *Burkholderia cepacia* species in the product. The sponsor provided a response to the IR in a document dated July 18, 2012. However, the response did not indicate if the drug product specification was updated to include the test method to demonstrate the absence of *B. cepacia*. This information was requested from the sponsor in an IR letter dated August 13, 2012. Sponsor's response to both IR letters dated February 28, 2012 and August 13, 2012 is included in the final review of this NDA. Initial Quality Assessment was provided by Chhagan Tele on January 18, 2012.

filename: N203479R1

Executive Summary**I. Recommendations**

- A. Recommendation on Approvability** – Recommend approval.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – N/A

II. Summary of Microbiology Assessments


- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** –Clozapine Oral Suspension is manufactured using (b) (4)


- B. Brief Description of Microbiology Deficiencies** - none
- C. Assessment of Risk Due to Microbiology Deficiencies** – N/A

III. Administrative

- A. Reviewer's Signature** _____
Vinayak B. Pawar, Ph.D., NDMS, OPS, CDER
- B. Endorsement Block** _____
Bryan S. Riley, Ph.D., NDMS, OPS, CDER
- C. CC Block**
N/A

10 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page



This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

VINAYAK B PAWAR
08/22/2012

BRYAN S RILEY
08/22/2012
I concur.